Atara Biotherapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Atara Biotherapeutics, Inc. on September 22, 2016. The report discloses a specific corporate governance event regarding executive compensation approved by the Compensation Committee of the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel compensation adjustments and does not contain financial performance data.
Material Changes
The material change disclosed is an increase in the base salary for Heather D. Turner, effective October 1, 2016. The increase is in connection with an expansion of her responsibilities at the company.
- Previous Base Salary: $342,990
- New Base Salary: $355,350
- Effective Date: October 1, 2016
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, outlook, management commentary on business strategy, risks, contingencies, or unusual items. The document is limited to the disclosure of the salary adjustment.
Key Facts for Investor Verification
- Verify the effective date of the salary increase (October 1, 2016).
- Confirm the specific nature of the "increase in responsibilities" for Heather D. Turner to assess the justification for the compensation adjustment.
- Note that this filing does not impact the company's reported financial statements for the period ending September 22, 2016.